Abemaciclib + Ruxolitinib combination
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-03 — A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis: Trial-early: Phase 1/2 study evaluating abemaciclib (CDK4/6 inhibitor) added to ruxolitinib backbone in primary and post-PV/post-ET myelofibrosis for safety and preliminary efficacy — introduces cell-cycle (CDK4/6) inhibition as a novel mechanistic add-on to the ruxolitinib combination portfolio. (novelty: 3)
Open questions
Related
Contributing findings
A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
03-sep-2026
novelty 3
per-area 3
introduces